T1	p 18 135	patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin
T2	p 401 449	patients with metastatic breast cancer ( MBC ) .
T3	p 634 655	( n = 509 ) ( O'Brien
T4	i 124 172	doxorubicin or pegylated liposomal doxorubicin :
T5	i 314 396	chemotherapy with doxorubicin ( DOX ) or a pegylated liposomal formulation ( PLD )
T6	i 524 598	DOX ( 60 mg/m ( 2 ) every 3 weeks ) or PLD ( 50 mg/m ( 2 ) every 4 weeks )
T7	i 618 625	therapy
T8	i 648 655	O'Brien
T9	i 1378 1390	chemotherapy
T10	i 1393 1407	DOX versus PLD
T11	i 1813 1859	granulocyte colony stimulating factor or PLD )
T12	i 1938 1950	chemotherapy
T13	o 720 745	absolute neutrophil count
T14	o 831 842	neutropenia
T15	o 846 857	neutropenia
T16	o 1259 1305	performance status , absolute neutrophil count
T17	o 1527 1536	threshold
T18	o 1541 1552	sensitivity